Exelixis (NASDAQ:EXEL) Price Target Raised to $47.00

Key Points

• Price target raised: Stifel Nicolaus lifted its Exelixis price target from $44 to $47 while maintaining a "hold" rating, and the stock's consensus analyst rating is "Hold" with a consensus price target of $47.44.
• Strong Q1 results and shareholder action: Exelixis beat Q1 EPS estimates ($0.87 vs. $0.75) with revenue of $610.8M (up 10% year‑over‑year) and announced a $750M share buyback that management says will be EPS‑accretive.
• Insider selling notable: Company insiders sold 362,849 shares worth about $15.9M in the past three months, while insiders still own 2.6% of the company.

Exelixis (NASDAQ:EXEL - Get Free Report) had its price target hoisted by research analysts at Stifel Nicolaus from $44.00 to $47.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a "hold" rating on the biotechnology company's stock. Stifel Nicolaus' price objective points to a potential downside of 0.98% from the company's previous close.

A number of other brokerages have also recently issued reports on EXEL. Wells Fargo & Company raised their target price on Exelixis from $35.00 to $40.00 and gave the stock an "equal weight" rating in a report on Wednesday. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a report on Thursday, March 5th. Wall Street Zen cut Exelixis from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 18th. Royal Bank Of Canada cut their price objective on Exelixis from $46.00 to $43.00 and set a "sector perform" rating on the stock in a report on Monday, March 2nd. Finally, Morgan Stanley lifted their price objective on Exelixis from $48.00 to $49.00 and gave the company an "equal weight" rating in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $47.44.

Exelixis Stock Performance

EXEL traded up $3.05 during midday trading on Wednesday, reaching $47.47. 2,752,299 shares of the company were exchanged, compared to its average volume of 2,710,657. Exelixis has a one year low of $33.76 and a one year high of $49.62. The stock has a market capitalization of $12.06 billion, a P/E ratio of 17.18, a PEG ratio of 0.99 and a beta of 0.38. The stock's 50-day simple moving average is $43.32 and its 200 day simple moving average is $42.86.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $610.81 million for the quarter, compared to analysts' expectations of $607.51 million. During the same quarter last year, the business earned $0.55 earnings per share. The company's revenue was up 10.0% compared to the same quarter last year. On average, research analysts anticipate that Exelixis will post 3.07 earnings per share for the current year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 67,814 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. The trade was a 15.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christopher J. Senner sold 30,617 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the sale, the chief financial officer owned 976,092 shares in the company, valued at $42,625,937.64. The trade was a 3.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 362,849 shares of company stock worth $15,917,463. Corporate insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On Exelixis

Several institutional investors have recently bought and sold shares of EXEL. Richardson Financial Services Inc. lifted its stake in Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 292 shares in the last quarter. Anchor Investment Management LLC increased its position in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 500 shares during the last quarter. Motiv8 Investments LLC acquired a new position in shares of Exelixis during the 4th quarter worth approximately $26,000. Root Financial Partners LLC acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $28,000. Finally, Acumen Wealth Advisors LLC acquired a new position in shares of Exelixis during the 4th quarter worth approximately $29,000. Institutional investors own 85.27% of the company's stock.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q1 EPS beat and margin improvement — Exelixis reported $0.87 GAAP EPS vs. $0.75 consensus and showed strong profitability metrics, which supports near‑term earnings visibility. Exelixis (EXEL) Tops Q1 Earnings Estimates
• Positive Sentiment: $750M buyback announced and management commentary — Company disclosed a $750M repurchase authorization tied to buyback‑driven EPS accretion, a clear driver of shareholder value and a reason for the stock’s upward move. Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback
• Positive Sentiment: Analysts lift targets and reiterate buys — Several firms raised price targets (e.g., TD Cowen to $55 and Morgan Stanley to $50) or reiterated bullish views citing Cabo durability and buyback EPS support, which underpins the rally. Exelixis Price Target Raised to $55 Price Target Raised to $50 (Morgan Stanley)
• Neutral Sentiment: Revenue roughly flat to expectations — Q1 revenue of ~$610.8M was essentially in line with consensus (slight miss in some reports), and FY2026 revenue guidance was reiterated/updated to about $2.5–2.6B, leaving room for debate about growth pacing vs. street models. Exelixis (EXEL) Tops Q1 Earnings Estimates (Yahoo)
• Neutral Sentiment: Conference call and transcripts available — Management discussed Cabo durability, Zanzalintinib regulatory timelines (December PDUFA for CRC filing referenced) and execution priorities; useful for investors wanting detail but not an immediate price catalyst. Earnings Call Transcript Earnings Call Summary
• Negative Sentiment: Cabometyx sales momentum mixed — Some reports note Cabometyx sales lagged estimates, and analysts flag competitive pressure and pipeline uncertainty as risks to sustained top‑line growth. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
• Negative Sentiment: Mixed analyst stance — Some firms (e.g., Wells Fargo) raised price targets but kept neutral/equal‑weight ratings, signaling potential downside from current levels and that enthusiasm is not unanimous. Benzinga (Wells Fargo note)

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.